DiscoverOri SpotlightSanjay Srivastava: Are CGTs Developing into a Commercial Dead-End?
Sanjay Srivastava: Are CGTs Developing into a Commercial Dead-End?

Sanjay Srivastava: Are CGTs Developing into a Commercial Dead-End?

Update: 2024-01-08
Share

Description

In this episode of the Ori Spotlight Podcast, we're joined by Sanjay Srivastava, Managing Director of Accenture's Cell and Gene Therapy Practice. With his extensive background in consulting and a deep understanding of the biotechnology sector, Sanjay offers unique insights into the rapidly evolving world of cell and gene therapies.

Sanjay and Jason C. Foster delve into the critical challenges facing the industry, particularly focusing on the scalability and efficiency of manufacturing processes. They discuss how these challenges impact the commercial viability of advanced therapies and the necessity of adapting our current healthcare systems to better accommodate innovative treatments.

Learn more about Sanjay here: https://www.linkedin.com/in/nitreniumions/

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Sanjay Srivastava: Are CGTs Developing into a Commercial Dead-End?

Sanjay Srivastava: Are CGTs Developing into a Commercial Dead-End?

Ori Biotech